DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Funds preclinical-to-IND-enabling work on an ALS drug that already has proof-of-concept efficacy data and a lead compound in hand.
About
By the time a treatment reaches this award, the easy question — does it work at all, even a little — is supposed to already be answered. This funds the expensive middle stretch: turning a validated lead into something ready for an FDA Investigational New Drug application.
The bar to enter is concrete. An application needs a lead compound already in hand, with proof-of-concept efficacy data from a…
Biotech
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.